ATLANTA, Nov. 16, 2007 (PRIME NEWSWIRE) -- Tikvah Therapeutics, Inc., an Atlanta, GA-based biopharmaceutical company focused on new treatment options to better manage central nervous system diseases, announced today that Dr. Harold H. Shlevin, president and chief executive officer of Tikvah, is scheduled to present at the Lazard Capital Markets Fourth Annual Healthcare Conference. The presentation will take place in New York on Tuesday, November 27, 2007, at 9:00 am EST.
An internet webcast of the presentation will be available live at http://www.wsw.com/webcast/lz4/tikvah/.
About Tikvah Therapeutics, Inc.
Atlanta-based Tikvah Therapeutics, Inc. focuses on exploring new uses for late-stage pharmaceutical compounds in selected therapeutic indications of central nervous system diseases, including neurology and psychiatry disorders. Its focus is on new therapeutic uses which have been confirmed in multiple, clinical proof-of-concept studies. This strategy aims to shorten product development timelines and substantially decreases the risk associated with the research and development efforts. A second prong of its strategy is to focus on specialized products with multiple stepping-stone indications and strong patent protections, thus helping to ensure long product life cycles and manageable commercial risk. For further information, please see www.tikvahtherapeutics.com
The Tikvah Therapeutics, Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=3966
"Tikvah Therapeutics, Inc.," "Bringing Hope to Life," and the logo design are trademarks of Tikvah Therapeutics, Inc., Atlanta, Georgia USA